The Case for  -Adrenergic Blockade as Prophylaxis Against Perioperative Cardiovascular Morbidity and Mortality
Craig H. Selzman, MD;
Stephanie A. Miller, MD;
Michael A. Zimmerman, MD;
Alden H. Harken, MD
Arch Surg. 2001;136:286-290.
Perioperative morbidity and mortality are frequently cardiac in origin. Many studies have prospectively attempted to define risk factors for cardiac ischemic events. Although we can now identify high-risk patients, optimal cardioprotective management strategies remain unclear. Treatment with  -adrenergic antagonists decreases myocardial oxygen consumption and is generally well tolerated. This article reviews the physiologic and clinical basis for using these agents as prophylaxis against cardiovascular events in high-risk surgical patients.
From the Division of Cardiothoracic Surgery, Department of Surgery, University of Colorado Health Sciences Center, Denver.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
This Month in Archives of Surgery
Arch Surg. 2001;136(3):259.
FULL TEXT
Archives of Surgery Reader's Choice: Continuing Medical Education
Arch Surg. 2001;136(3):361.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Brain death leads to abnormal contractile properties of the human donor right ventricle
Harken
J. Thorac. Cardiovasc. Surg. 2006;132:10-11.
FULL TEXT
Perioperative Beta-Blocker Therapy and Mortality after Major Noncardiac Surgery
Lindenauer et al.
NEJM 2005;353:349-361.
ABSTRACT
| FULL TEXT
Effect of beta blockers after coronary artery bypass in postinfarct patients: what can we learn from available literature?
Geraci and Haan
Ann. Thorac. Surg. 2002;74:1727-1732.
ABSTRACT
| FULL TEXT
|
